Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines

Abstract

This paper provides examples of defining estimands in real-world scenarios following ICH E9(R1) guidelines. Detailed discussions on choosing the estimands and estimators can be found in our companion papers. Three scenarios of increasing complexity are illustrated. The first example is a proof-of-concept trial in major depressive disorder where the estimand is chosen to support the sponsor decision on whether to continue development. The second and third examples are confirmatory trials in severe asthma and rheumatoid arthritis respectively. We discuss the intercurrent events expected during each trial and how they can be handled so as to be consistent with the study objectives. The estimands discussed in these examples are not the only acceptable choices for their respective scenarios. The intent is to illustrate the key concepts rather than focus on specific choices. Emphasis is placed on following a study development process where estimands link the study objectives with data collection and analysis in a coherent manner, thereby avoiding disconnect between objectives, estimands, and analyses.

Keywords

estimands clinical trials intercurrent events

Get full access to this article

View all access options for this article.

References

ICH Harmonised Guideline E9(R1). Estimands and Sensitivity Analysis in Clinical Trials. Step 1 version dated 16 June 2017.

Ratitch

Bell

Mallinckrodt

. Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) into Practice. Submitted to Therapeutic Innovation & Regulatory Science. 2018.

Mallinckrodt

Bell

Ratitch

. Technical and Practical Considerations in Aligning Estimators with Estimands in Clinical Trials. Submitted to Therapeutic Innovation & Regulatory Science. 2018.

Kessler

Berglund

Demler

Jin

Merikangas

Walters

. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602.

Mitchell

Trangle

Degnan

. Institute for Clinical Systems Improvement. Adult Depression in Primary Care; 2013. http://pcptoolkit.beaconhealthoptions.com/wp-content/uploads/2016/02/ICSI_Depression.pdf. Accessed March 27, 2019.

Practice guideline for the treatment of patients with major depressive disorder, third edition. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Published 2010. Accessed March 27, 2019.

Major Depressive Disorder: Developing drugs for treatment guidance for industry, draft guidance, revision 1. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM611259.pdf. Published June 2018. Accessed March 27, 2019.

Potter

Mallinckrodt

Detke

. Controlling placebo response in drug development: lessons from psychopharmacology. Pharm Med. 2014;28:53–65.

Mallinckrodt

Tamura

Tanaka

. Improving signal detection and reducing placebo response in psychiatric clinical trials. J Psychiatr Res. 2011;45:1202–1207.

10.

Goldstein

Mallinckrodt

Demitrack

. Duloxetine in the treatment of major depression: A double-blind clinical trial. J Clin Psychiatry. 2002;63(3):225–231.

11.

Williams

Kobak

Bech

. The GRID-HAMD: standardization of the Hamilton Depression Rating Scale. Int Clin Psychopharmacol. 2008;23(3):120–129.

12.

National Research Council. The Prevention and Treatment of Missing Data in Clinical Trials. Panel on Handling Missing Data in Clinical Trials, Committee on National Statistics, Division of Behavioral and Social Sciences and Education. Washington, DC: The National Academies Press; 2010.

13.

Mallinckrodt

Lipkovich

. A practical guide to analyzing longitudinal clinical trial data. Boca Raton, FL: Chapman and Hall/CRC; 2017.

14.

Ratitch

O’Kelly

Tosiello

. Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models. Pharm Stat. 2013;12(6):337–47.

15.

Global Asthma Network. The Global Asthma Report. http://globalasthmareport.org. Published 2014.

16.

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. www.ginasthma.org. Published 2018. Accessed March 27, 2019.

17.

Busse

Pedersen

Pauwels

. The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) Study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol. 2008;121(5):1167–1174.

18.

European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical investigation of medicinal products for the treatment of asthma. Version 22, October 2015. http://www.ema.europa.eu. Accessed March 27, 2019.

19.

Bleecker

FitzGerald

Chanez

. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127.

20.

Food and Drug Administration, Center for Drug Evaluation and Research. Application Number: 761070Orig1s000, Clinical Review(s); 2017. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761070Orig1s000MedR.pdf. Accessed March 27, 2019.

21.

Food and Drug Administration, Center for Drug Evaluation And Research. Application Number: 761070Orig1s000, Statistical Review(s); 2017. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761070Orig1s000StatR.pdf. Accessed March 27, 2019.

22.

European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Fasenra Assessment Report; 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004433/WC500245333.pdf. Accessed March 27, 2019.

23.

Keene

Jones

MRK

Lane

Anderson

. Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study. Pharm Stat. 2007;6:89–97.

24.

Keene

Roger

Hartley

Kenward

. Missing data sensitivity analysis for recurrent event data using controlled imputation. Pharm Stat. 2014;13:258–264.

25.

Akacha

Bretz

Ruberg

. Estimands in clinical trials—broadening the perspective. Stat Med. 2017;36(1):5–19.

26.

Smolen

Steiner

. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003;2:473–488.

27.

Colmegna

Ohata

Menard

. Current understanding of rheumatoid arthritis therapy. Clin Pharmacol Ther. 2012;91:607–620.

28.

Smolen

Breedveld

Burmester

. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3–15.

29.

Felson

Smolen

Wells

. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70:404–413.

30.

Klareskog

Catrina

Paget

. Rheumatoid arthritis. Lancet. 2009;373(9664):659–672.

31.

Food and Drug Administration. Guidance for Industry: Rheumatoid arthritis: developing drug products for treatment, draft dated May 2013. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm354468.pdf. Accessed March 27, 2019.

32.

Keystone

Genovese

Klareskog

. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009;68:789–796.

33.

Radner

Alasti

Smolen

Aletaha

. Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. Arthritis Res Ther. 2015;17:203.

34.

Wang

Pocock

. A win ratio approach to comparing continuous non-normal outcomes in clinical trials. Pharm Stat. 2016;15:238–245.

35.

Permutt

. Trimmed means for symptom trials with dropouts. Pharm Stat. 2017;16:20–28.

36.

Carpenter

Roger

Kenward

. Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple imputation. J Biopharm Stat. 2013;23(6):1352–1371.

37.

O’Kelly

Ratitch

. Clinical Trials With Missing Data: A Guide for Practitioners. West Sussex, UK: John Wiley & Sons, Inc.; 2014.

38.

Strand

Balbir-Gurman

Pavelka

. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. Rheumatology. 2006;45:1505–1513.